Ironwood Pharmaceuticals has announced that LINZESS has been approved by the US Food and Drug Administration (FDA) as a once-daily treatment for functional constipation in pediatric patients aged six to 17 years old. Functional constipation is a chronic condition characterized by hard, infrequent bowel movements that are often difficult or painful to pass, affecting an estimated six million children in the US. LINZESS is developed and marketed by AbbVie and Ironwood Pharmaceuticals in the United States. The FDA approval was based on the results of a large, multicenter, double-blind, Phase III study evaluating LINZESS in patients ages 6-17 years-old with functional constipation. This approval brings a much-needed option to an estimated 6 million 6-17-year-olds in the U.S affected by this chronic condition.
Keywords: Ironwood Pharmaceuticals, LINZESS, FDA, functional constipation, pediatric patients.
Ironwood Pharmaceuticals has received FDA approval for its drug LINZESS as a treatment for functional constipation in pediatric patients aged six to 17 years old. The drug is now available for immediate use across most of America. Functional constipation affects approximately six million children within this age range across America and can cause significant distress for both children and their families. The